BRPI0608176A2 - usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer - Google Patents

usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer

Info

Publication number
BRPI0608176A2
BRPI0608176A2 BRPI0608176-2A BRPI0608176A BRPI0608176A2 BR PI0608176 A2 BRPI0608176 A2 BR PI0608176A2 BR PI0608176 A BRPI0608176 A BR PI0608176A BR PI0608176 A2 BRPI0608176 A2 BR PI0608176A2
Authority
BR
Brazil
Prior art keywords
combination
pharmaceutical composition
cancer treatment
bcr
pharmaceutical compositions
Prior art date
Application number
BRPI0608176-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Francis Y F Lee
Roberto Weinmann
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0608176A2 publication Critical patent/BRPI0608176A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0608176-2A 2005-04-13 2006-04-13 usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer BRPI0608176A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US74843305P 2005-12-08 2005-12-08
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer
PCT/US2006/013773 WO2006113304A2 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
BRPI0608176A2 true BRPI0608176A2 (pt) 2009-11-17

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608176-2A BRPI0608176A2 (pt) 2005-04-13 2006-04-13 usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer

Country Status (12)

Country Link
US (2) US20060235006A1 (enExample)
EP (1) EP1868435A4 (enExample)
JP (1) JP2008536853A (enExample)
KR (1) KR20080004495A (enExample)
AU (1) AU2006236812A1 (enExample)
BR (1) BRPI0608176A2 (enExample)
CA (1) CA2604581A1 (enExample)
EA (1) EA200702238A1 (enExample)
MX (1) MX2007012537A (enExample)
NO (1) NO20075087L (enExample)
TW (1) TW200722091A (enExample)
WO (1) WO2006113304A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366932C (en) * 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
US8247419B2 (en) * 2005-06-09 2012-08-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2007059143A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
JP2009532438A (ja) * 2006-04-07 2009-09-10 ノバルティス アクチエンゲゼルシャフト 白血病の処置のためのピリミジルアミノベンズアミド化合物との組合せでのｃ−Ｓｒｃ阻害剤の使用
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009076373A1 (en) * 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
EP3175853B1 (en) * 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
US20100233172A1 (en) * 2008-12-16 2010-09-16 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
CN102665756A (zh) * 2009-10-01 2012-09-12 Csl有限公司 费城染色体阳性白血病的治疗方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2366932C (en) * 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
AU2003259717A1 (en) * 2002-08-07 2004-02-25 Bristol-Myers Squibb Company Modulators of rabggt and methods of use thereof
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
MY144177A (en) * 2004-02-04 2011-08-15 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Also Published As

Publication number Publication date
WO2006113304A2 (en) 2006-10-26
TW200722091A (en) 2007-06-16
CA2604581A1 (en) 2006-10-26
US20060235006A1 (en) 2006-10-19
EP1868435A4 (en) 2009-04-01
MX2007012537A (es) 2007-12-10
NO20075087L (no) 2008-01-09
US20090054415A1 (en) 2009-02-26
AU2006236812A1 (en) 2006-10-26
WO2006113304A3 (en) 2007-08-02
JP2008536853A (ja) 2008-09-11
KR20080004495A (ko) 2008-01-09
EP1868435A2 (en) 2007-12-26
EA200702238A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
NO20075087L (no) Kombinasjoner, metoder og sammensetninger for behandling av cancer
NO20075154L (no) Formuleringer av en src/abl-inhibitor
AR112118A2 (es) Inhibidores de pi-3 quinasa
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
BRPI0922642B8 (pt) formas polimórficas de sal de cloridrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetóxi)-pirimidin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila,seus processos de fabricação, composição farmacêutica, medicamento, e kit
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
BRPI0815715A8 (pt) Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
CA2542105A1 (en) Compounds and compositions as protein kinase inhibitors
NO20081963L (no) Fremgangsmate for behandling
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
Shastry et al. Homocysteine induces mesangial cell apoptosis via activation of p38-mitogen-activated protein kinase
WO2007116025A3 (en) Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
MX2023012521A (es) Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas.
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
UY29964A1 (es) Formas de cristal f,g,h,i, y k del mesilato de imatinib
MX2009003974A (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.